HER1/EGFR Inhibitor-Associated Rash: Future Directions for Management and Investigation Outcomes from the HER1/EGFR Inhibitor Rash Management Forum

HER1/EGFR Inhibitor-Associated Rash: Future Directions for Management and Investigation Outcomes from the HER1/EGFR Inhibitor Rash Management Forum Román Pérez-Soler, Jean Pierre Delord, Allan Halpern, Karen Kelly, James Krueger, Bartomeu Massutí Sureda, Joachim von Pawel, Jennifer Temel, Salvatore Siena, Denis Souličres, Leonard Saltz, James Leyden Oncologist 2005; 10: 345-356 Author Information and Disclosures Target Audience: Physicians who wish to advance their current knowledge of clinical cancer medicine in symptom management and are involved in providing patient care in a cancer care environment. Method of Physician Participation: Read course materials, complete course quiz and evaluation form (optional). Learning Objectives After completing this course, the reader should be able to: Describe the clinical and pathological characteristics of the cutaneous rash secondary to anti-EGFR therapy. Explain the prognostic implications of the cutaneous rash secondary to anti-EGFR therapy. Discuss the treatment of the cutaneous rash secondary to anti-EGFR therapy. The NIH/FAES designates this educational activity for a maximum of 1 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

CME Activity Information Accreditation CME Instructions For Credit Privacy Statement Hardware/Software Requirements Release Date: Apr. 26, 2005 Most Recent Review: Apr. 26, 2005* Most Recent Update: Apr. 26, 2005 Date Credit Expires: Apr. 26, 2007 Time to Complete: 1 hour Medium: Internet Online *Click here to learn more about our review process.